LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Hirotsugu Kenmotsu(Shizuoka Cancer Center), Toshiaki Takahashi(Okayama University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Kazushige Wakuda(Shizuoka Cancer Center), Satoru Miura(Niigata Cancer Center Hospital), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Keisuke Kirita(Hakodate Central General Hospital), Shunsuke Teraoka(Wakayama Medical University), T. Kato(Kanagawa Prefectural Hospital Organization), Isamu Okamoto(Kyushu University Hospital), Yuki Sato(Goethe University Frankfurt), Keita Mori(Shizuoka Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Ryo Koyama(Japan Proton Accelerator Research Complex), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Ryo Toyozawa(National Hospital Organization Kyushu Cancer Center), Ken Masuda(Hiroshima City Asa Citizens Hospital), Nobuyuki Yamamoto(Wakayama Medical University)
Cited by 17
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k